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1272The Costs and Cost-Effectiveness of Allogeneic
Peripheral Blood Stem Cell Transplantation versus
Bone Marrow Transplantation in Pediatric Patients
with Acute Leukemia
Yu-Feng Lin,1,2 David R. Lairson,2 Wenyaw Chan,2
Xianglin L. Du,2 Kathryn S. Leung,1 Alana A. Kennedy-Nasser,1
Caridad A. Martinez,1 Stephen M. Gottschalk,1 Catherine M. Bollard,1
Helen E. Heslop,1 Malcolm K. Brenner,1 Robert A. Krance1In a retrospective study, we evaluated the cost and cost-effectiveness of allogeneic peripheral blood stem cell
transplantation (PBSCT) (n5 30) compared with bone marrow transplantation (BMT) (n5 110) in children
with acute leukemia after 1 year of follow-up. Treatment success was defined as disease-free survival at 1 year
posttransplantation. For patients at standard risk for disease, the treatment success rate was 57.1% for
PBSCTrecipients and 80.3% for BMTrecipients (P 5 not significant [NS]). The average total cost per treat-
ment success at 1 year in the standard-risk disease group was $512,294 for PBSCTrecipients and $352,885
for BMTrecipients (P 5 NS). For patients with high-risk disease, the treatment success rate was 18.8% for
PBSCTrecipients and 23.5% for BMTrecipients (P5NS). The cumulative average cost was $457,078 in BMT
recipients and $377,316 in PBSCTrecipients (P5NS). Point estimates of the incremental cost-effectiveness
ratio (ICER) indicate that in patients with standard-risk disease, allogeneic BMT had lower costs and greater
effectiveness than PBSCT (ICER, -$687,108; 95% confidence interval [CI], $2.4 million to dominated). For
patients with high-risk disease, BMTwas more effective and more costly, and it had an ICER of $1.69 million
(95% CI, $29.7 million to dominated) per additional treatment success. The comparative economic evalua-
tion provides support for BMT in standard-risk patients, but much uncertainty precludes a clear advantage of
either treatment option in patients with high-risk disease. More studies using larger and randomized
controlled trials are needed to confirm the long-term cost-effectiveness of each procedure.
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Advances in stem cell transplantation (SCT) tech-
nology have improved the outcome and increased the
availability of the technique, encouraging its use as
a front-line treatment for many serious malignant and
nonmalignant disorders. Although bone marrow (BM)
was initially the exclusive sourceof stemcells, peripheral1Center for Cell and Gene Therapy, Department of Pedi-
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6/j.bbmt.2010.03.016blood stem cells (PBSCs) have become an increasingly
favored alternative. Indeed, PBSCs have now largely
superseded BM as the source of cells in autologous
SCT, because of preferable clinical outcomes, such as
faster engraftment kinetics and shorter hospitalization
times [1-3]. Whereas allogeneic PBSC transplantation
(PBSCT) produces similar benefits in the allogeneic
setting, these are partially offset by the association of
this stem cell source with an increased risk of graft-
versus-host disease (GVHD), which remains even with
recent improvements in GVHD prophylaxis and
molecular techniques for establishing donor–recipient
histocompatibility [4-10]. Consequently, whether
PBSCs are preferable to BM as an allograft source is
unclear. In practice, BM continues to be the main
source of stem cells for matched sibling donor and
matched unrelated donor transplantations, whereas
PBSCs are used more widely for haploidential
transplantation, because this source allows for
increased stem cell doses, with apparently beneficial
Biol Blood Marrow Transplant 16:1272-1281, 2010 1273Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Childreneffects on engraftment [11-13]. Umbilical cord blood,
a third source of stem cells for allogeneic SCT, might
be associated with a lower incidence of severe GVHD
compared with the alternatives [14]. The use of umbili-
cal cord blood has significant limitations, however,
including greatly delayed time to hematologic recovery
and increased risk of infection, both of which lead to
higher overall costs [15].
Although allogeneic SCT with PBSCs or BM offers
the prospect of a permanent cure, few studies have
addressed the overall costs and cost-effectiveness of the
procedure or compared the cost-effectiveness of these 2
stem cell sources. Previous adult studies have compared
the cost-effectiveness of each source, but there are little
cost comparison data in the pediatric population [16-
20]. This is a significant deficiency, because the disease
mix (eg, acute lymphocytic leukemia [ALL] . acute
myelogenous leukemia [AML]), the biology of the
diseases, and the risks of severe GVHD are all strikingly
different in the pediatric and adult populations. These
differences might result in differing predispositions to
posttransplantation complications and differing overall
outcomes, and thus cost-effectiveness assessments.
In the present work, we compared the costs and
cost-effectiveness of allogeneic PBSCT and BM trans-
plantation (BMT) in pediatric patients with acute
leukemia.We examined the 1-year posttransplantation
economic implications of PBSCT versus BMT by
stratifying patients’ disease status in a retrospective
study derived from a single institution in which
patients underwent primary transplantation between
2001 and 2006.PATIENTS AND METHODS
Patients
We studied children and adolescents (age range,
0-18 years) with acute leukemia who underwent alloge-
neic PBSCT or BMT between January 1, 2001, and
September 30, 2006, in the Stem Cell Transplant
Unit atTexasChildren’sHospital (TCH).Weanalyzed
those patients who received a primary transplantation
and had acute leukemia as their primary disease. In
our cohort, standard risk was defined as ALL or AML
in first or second remission, and high risk was defined
as ALL or AML in third or subsequent remission or
in relapse or in patients with secondary AML [21].
The study protocol was approved by the Institutional
Review Boards at Baylor College of Medicine and
TCH.Study Design
The data collection period consisted of the trans-
plantation phase (admitted for initiation of pretrans-
plantation chemotherapy until hospital discharge),short-term follow-up (after initial hospitalization to
100 days posttransplantation), and long-term follow-
up (100 days to 1 year posttransplantation). Medical
records were retrospectively reviewed for demographic
data, date of engraftment, duration of hospital stay,
onset of acute andchronicGVHD(aGVHD,cGVHD),
incidence of infectious complications, and duration of
disease-free survival. Data were obtained from the elec-
tronicmedical records systemofTCH’sCenter forCell
and Gene Therapy using StemSoft (Vancouver BC,
Canada) and Logician (Centricity Physician Office
EMR, Hillsboro, Oregon, USA) software to ensure
thorough and consistent counting of resource use.
The source of stem cells for the allograft was
determined by each patient’s physician based on avail-
ability. The HLA typing method varied by year of
transplantation, with high resolution of both class I
(HLA-A, -B, -C) and class II (HLA-DRB1) antigens
used starting on June 1, 2005. When a potential trans-
plantation candidate lacked an HLA-genotypically
identical sibling donor or there was insufficient time
to search for a suitable donor, a stem cell graft from
a haploidentical related donor was considered. Before
2003, 93% of the patients underwent BMT. After
2003, 30% of the patients underwent PBSCT. BM
and PBSC collection was done following institutional
standard operating procedures. Myelogenous engraft-
ment and grading of aGVHD or cGVHD were
evaluated by standard criteria [22].Cost Analysis
Cost data were retrospectively acquired from
administrative records, and cost estimates were based
on micro-cost information from the internal account-
ing system. At TCH, the decision support system con-
tains patient demographic and utilization data and can
be used along with the general ledger accounting and
payroll data to allow financial analysis of each hospital
encounter. The general ledger and payroll expenses
are input into the system. These costs, along with rel-
ative value units or cost weights assigned at the product
level, create a cost per procedure, and these data are
accumulated and further summarized to create a total
cost per visit. The database comprised cost data from
October 1, 2003, to September 30, 2007. Data from
beyond October 1, 2007, were not validated at the
time the data were requested. Among the 140 patients
recruited for the study, we initially acquired the actual
costs for 57 patients in the BMT group and 19 patients
in the PBSCT group. All costs were adjusted to 2008
U.S. dollars according to the medical care component
of the Consumer Price Index [23].
The components of costs included days in hospital,
outpatient visits, intravenous treatments, nuclear
medicine, laboratory and diagnostic services, radiother-
apeutic and surgical procedures, blood products,
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stem cell collection before transplantation were not in-
cluded in the analysis, because the costs for BM harvest
andPBSCapheresiswere essentially identical ($9164.40
for harvest and $9285.32 for apheresis). Of the 30
patients who underwent PBSCT, 2 had more than one
PBSC collection. The aforementioned procurement
costs include laboratory tests and donor collection fees
but do not incorporate the costs of processing stem
cell products in the laboratory. Indirect costs were
excluded, because the perspective of this study was
that of health care providers and policy makers.
Because cost data were available only for patients
undergoing SCT after September 30, 2003, we devel-
oped a regression model with the available cost data to
predict the total cost for those patients admitted for
SCT between January 1, 2001, and September 30,
2003. Our regression equation included sex, ethnicity,
prognostic factors, and length of hospital stay and its
quadratic term, along with short-term and long-term
study endpoints. (See the Appendix for the regression
model and Table A1 for coefficients.) For the trans-
plantation phase, we included donor type, donor/
recipient cytomegalovirus (CMV) serostatus, disease
risk, and length of stay into the equation. For the
short-term follow-up, disease risk, occurrence of
aGVHD, and duration of inpatient stay were included
in the computation. For the long-term follow-up, dis-
ease risk, occurrence of cGVHD, infection or relapse,
and hospitalization were included. The equation was
used to predict the total costs by each phase of
treatment, and the imputation procedure was used
separately in the BMT and PBSCT groups. The
prediction method assumed that the hospital cost
allocation method used after September 30, 2003,
was also applicable to the previous period for which
cost data were not available. Stability in the institu-
tional allocation of expenses in the transplantation
unit during the study period was confirmed by the
accounting department. In addition, the cost distribu-
tion for outlier cases was examined using a normal
probability plot. Outliers were then excluded from
the estimation of the cost prediction model [24].Effectiveness Analysis
The BMT group served as the reference popula-
tion for the cost-effectiveness comparison with the
PBSCT group. Cost-effectiveness was measured at 1
year posttransplantation. Treatment outcome was de-
fined as treatment success during the 1-year follow-up
period up to the last date of contact as of December 31,
2007. Treatment was considered a success if the
patient survived disease-free for 1 year. Cost and sur-
vival information was censored at the time of disease
relapse or death during this 1-year follow-up period.
Incremental effectiveness was measured by the 1-yearposttransplantation difference in the percentage of
cases with treatment success (PBSCT minus BMT).
Incremental cost was measured by the 1-year post-
transplantation difference in the average cost (PBSCT
minus BMT). The incremental cost-effectiveness ratio
(ICER) was expressed as the incremental effect divided
by the incremental cost.
Descriptive Statistical Analyses
Descriptive statistics were used to summarize the
distribution of each variable and to compare baseline
characteristics between the PBSCT and BMT groups,
using SPSS 15.0 (SPSS Inc, Chicago, IL) and SAS 9.2
(SAS Institute, Cary, NC). Although the nature of the
population surveyed provided unequal numbers in
the groups, we allowed for the effects of these discrep-
ancies and used the Mann-Whitney U test to compare
the 2 groups on all continuous variables and itemized
costs in patients who had actual costs. The discrete
variables (eg, frequency of aGVHD and cGVHD and
infectious complications) were compared by means of
a frequency table using Fisher’s exact test. For all
statistical tests, P5 .05 was considered significant.
Uncertainty Analyses
Uncertainty was examined by standard sensitivity
analysis and probabilistic sensitivity analysis. Standard
one-way sensitivity analysis was used to examine the
effect of imputing cost data for patients treated before
October 1, 2003, with estimates of the mean cost both
with and without the imputed data. We considered
using bootstrap simulation to examine statistical
uncertainty; however, bootstrapping relies heavily on
the tails of the estimated sampling distribution, and
the smaller the sample, the less likely that all of the
relevant characteristics of the population will be repre-
sented [25]. Thus, our probabilistic sensitivity analysis
of the cost variables used 1000 Monte Carlo simula-
tions to estimate the 95% confidence intervals (CIs),
using TreeAge Pro 2009 Suite (TreeAge Software,
Williamstown, MA) [26-28].RESULTS
Patient and Transplant Characteristics
A total of 140 patients were consecutively recruited
during the study period, of whom110 underwent BMT
and 30 underwent PBSCT. Patient and transplant
characteristics are summarized in Table 1. The
PSBCT group included 14 standard-risk patients
(46.7%) and 16 high-risk patients (53.3%); corre-
sponding numbers in the BMT group were 76
(69.1%) and 34 (30.9%). In the PBSCT group, 14
patients had ALL (46.7%) and 16 had AML (53.3%);
in the BMT group, 74 patients had ALL (67.3%) and
36hadAML (32.7%). In thePBSCTgroup, 15 patients
Table 1. Patient and Transplant Characteristics
Characteristic BMT PBSCT P Value
Number of patients 110 30
Patient age, years, median (range) 8 (0-18) 9 (2-18)
Patient sex, males/females, n 64/46 19/11 NS
Disease risk, n (%) .021
Standard risk 76 (69.1) 14 (46.7)
High risk 34 (30.9) 16 (53.3)
Diagnosis, n (%) .033
ALL 74 (67.3) 14 (46.7)
AML 36 (32.7) 16 (53.3)
Ethnicity, n (%) NS
Caucasian 35 (31.8) 13 (43.3)
Black 13 (11.8) 3 (10.0)
Hispanic 57 (51.8) 12 (40.0)
Asian/other 5 (4.5) 2 (6.7)
Donor type, n (%) <.001
HLA-mismatched sibling/other relative 10 (9.1) 15 (50.0)
HLA-identical sibling 38 (34.5) 4 (13.3)
HLA-matched unrelated 49 (44.6) 9 (30.0)
HLA-mismatched unrelated 13 (11.8) 2 (6.7)
CD34 selection, n (%) <.001
Yes 2 (1.8) 13 (43.3)
No 108 (98.2) 17 (56.7)
Medicaid, n (%) NS
Yes 58 (52.7) 16 (53.3)
No 52 (47.3) 14 (46.7)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; BMT, bone marrow transplantation; PBSCT, peripheral blood
stem cell transplantation.
Table 2. Clinical Outcomes at 1-Year Follow-Up
Variable BMT PBSCT P Value
Time to engraftment, days, mean (SD)
Neutrophils 17.96 (3.475) 14.48 (3.355) <.001
Platelets 28.68 (15.069) 23.08 (9.499) .034
aGVHD grade II-IV, n (%) 17 (15.5%) 2 (6.7%) NS
cGVHD, n (%) 12 (10.9%) 4 (13.3%) NS
Infection, n (%) 80 (75.5%) 27 (90.0%) .028
Treatment outcomes, standard-risk group, n (%) NS
Success 61 (80.3%) 8 (57.1%)
Failure 15 (19.7%) 6 (42.9%)
Treatment outcomes, high-risk group, n (%) NS
Success 8 (23.5%) 3 (18.8%)
Failure 26 (76.5%) 13 (81.2%)
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; BMT, bone marrow transplantation; PBSCT,
peripheral blood stem cell transplantation.
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(13.3%) had a matched related donor, 9 (30.0%) had
a matched unrelated donor, and 2 (6.7%) had a mis-
matched unrelated donor. In the BMT group, the
stem cell source was an HLA-matched related donor
in 38 patients (34.5%), a matched unrelated donor in
49 patients (44.6%), and amismatched related or unre-
lated donor in 23 patients (20.9%). A significantly
higher percentage of PBSCT patients received CD34
selected allografts compared with the BMT group.
This variable was taken into account during multivari-
ate analyses and was not a significant risk factor for
acute or chronic GVHD (data not shown). There
were no statistically significant differences in terms of
patient age, sex, ethnicity, or insurance coverage
between the PBSCT and BMT groups.Clinical Outcomes
Asanticipated, the patients in thePBSCTgrouphad
significantly faster neutrophil and platelet engraftment
than those in the BMT group (P\.001 for neutrophils;
P5 .034 for platelets) (Table 2). The frequency of acute
or chronic GVHD was not statistically significantly
different between the groups; however, the incidence
of infectious complications was significantly higher in
the PBSCT group (P5 .028). At the 1-year follow-up,
61 (80.3%) of the standard-risk BMT patients were
disease-free, compared with 8 (57.1%) of the
standard-risk PBSCT patients (P 5 NS). Eight
(23.5%) high-risk BMT patients and 3 (18.8%) high-risk PBSCT patients were disease-free at the 1-year
follow-up.Cost Data
The average costs of treatment and follow-up per
category are presented in Table 3. The mean total
cost for the initial hospitalization was higher in the
PBSCT group compared with the BMT group, but
the difference was not statistically significant. Room
and board accounted for 50% of the total costs, and
pharmacy accounted for ~28.0% of the total costs.
Other major cost items during this initial phase
included blood products and laboratory and radiology
services. The average duration of hospitalization
(length of stay [LOS]) was 42.9 days in the PBSCT
group and 36.8 days in the BMTgroup. The total costs
over this time period were $282,577 6 $272,344 for
the PBSCT group and $208,987 6 $169,554 for the
BMT group (P 5 NS). Three outlier cases (1 PBSCT
patient and 2 BMT patients) accumulated.$1 million
in costs per patient; all of these patients subsequently
died of progressive disease during the initial hospitali-
zation period, leading to large cost and LOS variations
in both groups.
The costs of the short-term follow-up period (after
initial hospitalization to 100 days posttransplantation)
were higher in the PBSCT group ($147,907 for
PBSCT vs $103,428 for BMT). The average LOS
was 25 days in the PBSCT group and 19 days in the
BMT group. Room and board was identified as the
most costly category. During short-term follow-up,
PBSCT patients had more blood product and
pharmacy usage, consistent with their longer LOS.
We determined costs over the longer-term follow-
up period in patients who survived from 100 days
posttransplantation to the 1-year follow-up. The aver-
age total costs were similar in the 2 groups, $106,683
6 $76,577 for PBSCT patients versus $124,578
6 $147,207 for the BMT group, and the average
LOS was 14 days and 25 days, respectively. During
Table 3. Treatment and Follow-Up Costs per Patient in the
BMTand PBSCT Groups*
Variable
BMT, US$,
Mean (SD)
PBSCT, US$,
Mean (SD)
Costs of the initial
hospitalization
n 5 57 n 5 19
Blood products $9,392 ($16,560) $18,335 ($26,383)
Laboratory $16,503 ($17,914) $22,543 ($27,522)
Laboratory, pathology $2746 ($6071) $3428 ($4043)
Operating room $3277 ($3035) $3281 ($2811)
Pharmacy $59,582 ($62,168) $76,688 ($97,809)
Radiology, diagnostics $834 ($1677) $1317 ($2077)
Radiology, therapeutics $9544 ($4427) $9375 ($4823)
Room $104,052 ($59,444) $140,126 ($99,975)
Length of stay, days 36.84 (16.42) 42.89 (22.75)
Total costs $208,987 ($169,554) $282,577 ($272,334)
Costs of short-term
follow up (day 100
posttransplantation)
n 5 54 n 5 18
Blood products $8821 ($20,032) $13,758 ($25,175)
Laboratory $17,320 ($13,622) $19,384 ($14,095)
Laboratory, pathology $3542 ($2176) $4695 ($2385)
Operating room $2448 ($3355) $2206 ($2667)
Pharmacy $26,365 ($35,668) $33,509 ($33,040)
Radiology, diagnostics $868 ($1264) $1289 ($1503)
Radiology, therapeutics $3222 ($3690) $6825 ($9105)
Room $39,798 ($50,842) $60,435 ($66,348)
Length of stay, days 18.55 (16.80) 25.06 (20.84)
Total costs $103,428 ($123,929) $147,907 ($135,316)
Costs of long-term
follow-up (1 year
posttransplantation)
n 5 45 n 5 15
Blood products $12,234 ($15,903) $12,952 ($9458)
Laboratory $23,029 ($25,764) $15,484 ($11,019)
Laboratory, pathology $5220 ($3959) $5746 ($4740)
Operating room $3097 ($2923) $2192 ($1554)
Pharmacy $31,566 ($45,555) $22,670 ($20,265)
Radiology, diagnostics $1579 ($2161) $1641 ($1555)
Radiology, therapeutics $7471 ($9010) $1477
Hormone therapy $1957 ($2884) $614 ($447)
Room $43,295 ($57,758) $39,891 ($32,362)
Length of stay, days 25.07 (26.33) 14.36 (10.32)
Total costs $124,578 ($147,207) $106,683 ($76,577)
BMT indicates bone marrow transplantation; PBSCT, peripheral blood
stem cell transplantation.
*Actual cost data are available from the accounting system; all values are
presented in year 2008 dollars.
Table 4. Total Costs per Patient in the BMT and PBSCT
Groups at 1 Year Posttransplantation*
Treatment
Outcome
BMT, US$,
Mean (SD)
PBSCT, US$,
Mean (SD) P Value
Standard-risk group
Success $327,170 (156,654) $367,511 (164,382) NS
Failure $457,459 (357,503) $705,338 (297,292) .029
High-risk group
Success $438,473 (256,150) $263,392 (129,239) NS
Failure $462,803 (304,924) $403,606 (311,868) NS
BMT indicates bone marrow transplantation; PBSCT, peripheral blood
stem cell transplantation.
*Actual and imputed total costs were included.
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room and board accounted for about 60% of the total
costs in both groups.
The subgroup of patients with standard-risk dis-
ease had an average total cost per successfully treated
patient of $367,511 6 $164,382 in the PBSCT group
and $327,1706 $156,654 in the BMT group (P5NS)
(Table 4). In the subgroup of patients with high-risk
disease, the average cost per successfully treated
patient was $263,3926 $129,239 in the PBSCT group
and $438,473 6 $256,150 in the BMT group (P 5
NS). The cumulative cost of treatment intervention
was higher in the patients who relapsed or died before
the 1-year follow-up compared with those who
remained disease-free at 1 year. For these failing
patients, the average total cost in the standard-risk
subgroup was $705,338 6 $297,292 in the PBSCT
group versus $457,4596 $357,503 in the BMT group(P 5 .029). In the high-risk subgroup, this cost was
$403,606 6 $311,868 in the PBSCT group and
$462,803 6 $304,924 in the BMT group (P 5 NS).
At the 1-year follow-up, the cost of initial hospital-
ization for transplantation accounted for approxi-
mately 50% of the total costs, and short-term and
long-term follow-up costs accounted for 26% and
24%, respectively. In the standard-risk subgroup,
patients who did not achieve disease-free survival at 1
year of follow-up had 40%-92% higher costs com-
pared with those who had been treated successfully.
In the high-risk subgroup, this figure was 6%-53%.
Fourteen patients (3 in the BMT group and 11 in
the PBSCT group) underwent additional transplanta-
tion if they relapsed from their primary SCT. The
average total cost for these patients was $383,017
6 $143,513 in the PBSCT group and $262,299 6
$65,776 in the BMT group (data not shown). The
median survival time was 199 days (range, 10 to
.1700 days) in the PBSCT group compared with
150 days (range, 49-391 days) in the BMT group.Cost-Effectiveness Analysis
BMT served as the reference when computing the
ICERs for standard-risk and high-risk patients
(Table 5). For the standard-risk subgroup, the total
mean cost per patient was $512,294 6 $280,433 in
the PBSCT group and $352,885 6 $214,976 in the
BMT group. The treatment success rate was 57.1%
in the PBSCT group and 80.3% in the BMT group.
Compared with PBSCT, BMT had greater effective-
ness and lower costs (ICER, 2$687,108) in this sub-
group of patients. For the high-risk subgroup, the
average cost per patient was $377,316 6 $288,498 in
the PBSCT group and $457,078 6 $290,630 in the
BMT group. The probability of treatment success
was 18.8% for the PBSCT group and 23.5% for the
BMT group; 3 patients in the PBSCT group and 8
patients in the BMT group had been treated success-
fully at the 1-year follow-up. The ICER for the
high-risk subgroup was approximately $1.69 million
per additional treatment success in the BMT group
compared with the PBSC group.
Table 5. Cost-Effectiveness Analysis of SCT for Acute Leukemia in Children*
Total Cost (C) Incremental Cost (DC) Effectiveness (% treatment success) (E) Incremental Effectiveness (DE) ICER (DC/DE)
Standard-risk group
BMT $352,885 80.3%
PBSCT $512,294 $159,409 57.1% <0 2$687,108
High-risk group
BMT $457,078 23.5%
PBSCT $377,316 2$79,762 18.8% 24.7% $1,697,063
SCT indicates stem cell transplantation; BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; ICER, incremental cost-
effectiveness ratio.
*Actual and imputed total costs were included.
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The ICERs were recomputed to exclude imputed
costs to gauge the effect of the cost imputation process
on the underlying data (Table 6). In patients with
standard-risk disease, BMT remained dominant over
PBSCT (ICER, 2$969,453). The ICER was reduced
to $1.41 million in the analysis of high-risk patients,
with BMT more expensive and more effective than
PBSCT.
Results of the probabilistic sensitivity analyses are
shown in Figure 1 for the standard-risk subgroup
and in Figure 2 for the high-risk subgroup. The
mean cost was $515,540 6 $162,969 (95% CI,
$258,867 to -$890,989) for the standard-risk PBSCT
patients and $357,748 6 $146,874 (95% CI,
$132,581 to -$699,985) for the standard-risk BMT pa-
tients. The 95% CI ellipse shows that BMT was dom-
inant over PBSCT, and the 95% confidence limit for
the ICER ranged from $2.4 million to 2$5.5 million.
The majority of the points (76.7%) fell in quadrant II,
indicating a higher probability that PBSCT was less
effective and more costly (Figure 1). There was
a 19% probability for PBSCT being less costly, but
also less effective (quadrant III).
For high-risk patients, the mean cost was $386,193
6 $255,691 (95% CI, $70,297-$1,026,887) in the
PBSCT group and $468,244 6 $243,771 (95% CI,
$128,543-$1,030,401) in the BMT group. The 95%
confidence limits for the ICER ranged from $29.7 mil-
lion to 2$35.2 million. There is a 36.8% probability
that PBSCT would be less costly but also less effective
compared with BMT (quadrant III), as shown in
Figure 2. Furthermore, PBSCT has an equivalentTable 6. Uncertainty Analysis of Cost-Effectiveness Analysis
on Actual Cost Data
ICER (Actual and
Imputed Costs)
ICER
(Actual Costs)
Standard-risk group
BMT
PBSCT 2$687,108 2969,453
High-risk group
BMT
PBSCT $1,697,063 $1,415,362
BMT indicates bone marrow transplantation; PBSCT, peripheral stem
cell transplantation; ICER, incremental cost-effectiveness ratio.opportunity (24%) of being the dominant option
(quadrant IV) or being the dominated choice (quad-
rant II) over BMT.Overall, there is no clear preference
for either treatment method, because of the large
degree of uncertainty in the results.DISCUSSION
We report a cost-effectiveness analysis comparing
PBSCT and BMT in a cohort of pediatric patients.
Cost-benefit analyses measure both the costs and the
effectiveness of alternative treatments in monetary
units and thereby determine the net (social) benefit.
Our study measures effectiveness in terms of clinical
indicators/health outcomes and is the first to include
such cost-effectiveness endpoint analyses out to 1
year of follow-up. The clinical outcomes indicate
faster engraftment, but a higher frequency of infec-
tious complications, in patients receiving PBSCT
compared with those receiving BMT. Between-groupIncremental Effectiveness
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Figure 1. ICER of PBSCT (A) and BMT (B) in the standard-risk
subgroup. The ICER was determined using 1000 Monte Carlo simula-
tions to estimate the 95% confidence ellipse. Most points (77%) fell in
quadrant II, indicating a higher probability that PBSCTwas less effective
and more costly than BMT.
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Figure 2. ICER of PBSCT (A) and BMT (B) in the high-risk subgroup.
The ICER was determined using 1000 Monte Carlo simulations to esti-
mate the 95% confidence ellipse. There is a 37% probability that PBSCT
would be less costly but also less effective than BMT (quadrant III).
PBSCThas an equivalentopportunity (24%)of being the dominant option
(quadrant IV) or being the dominated choice (quadrant II) over BMT.
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cally significant. At the 1-year follow-up, patients in
the BMT group had a higher treatment success rate
and lower costs within the standard-risk subgroup
but not within the high-risk disease group, in which
both the treatment success rate and the cumulative
costs were lower in the PBSCT group.
Previous cost-effectiveness analyses of SCT versus
chemotherapy or no transplantation mostly studied
adult populations with heterogeneous diseases [29-35].
Several of these studies found that SCT was cost-
effective, with a cost of intervention of\$50,000 per
quality-adjusted life-year [32-35]. Comparisons of the
cost-effectiveness of PBSCT versus BMT have been
limited. Only one exclusively pediatric study analyzing
the cost-effectiveness of these 2 stemcell sources in chil-
dren with hematologic malignancy has been reported.
This single-institution study (Hospital Nino Jesus,
Spain) of 25 patients accrued over 9 years found lower
overall costs at 100 days posttransplantation for PBSCT
compared with BMT [36]. Although more adult
cost-effectiveness analyses have been published, these
investigated only acute costs [20,29,31,33].
In a separate study, we analyzed the impact of stem
cell source on disease-free survival (DFS) in the pedi-
atric transplantation population at 1 year and 3 years
of follow-up, respectively. In our series, Kaplan-
Meier analysis demonstrated a significant difference
in the cumulative probabilities of DFS in patients
undergoing BMT and those undergoing PBSCT.
However, multivariate Cox regression analysis showed
no effect of stem cell source on treatment-relatedmortality, relapse, or treatment failure overall, with
HLA typing, disease status at transplantation, the im-
pact of CD34 selection, and occurrence of aGVHD or
cGVHD also included as independent variables. In the
subgroups of patients with standard-risk and high-risk
disease, the estimated probabilities of survival did not
retain statistically significant differences between the
PBSCT and BMT groups. Of note, it was mostly
stem cells from haploidentical donors that were
CD34-selected, whereas nonselected PBSCs were
used mainly for matched unrelated donors. Our subse-
quent multivariate analysis to adjust for the indepen-
dent effects of potential risk factors found that CD34
selection was not associated with overall outcome.
We also analyzed the effect of age on outcome by
stem cell source and found no significant correlation
between graft type and age distribution. Ultimately,
only pretransplantation CMV seropositivity and
differing severity of underlying disease remained
significant risk factors for DFS.
By dividing our patients into standard-risk and
high-risk subgroups, we found that despite the faster
hematopoietic recovery observed in PBSCT recipients
after initial transplantation, there was no difference
from BMT recipients in LOS or costs incurred. In
addition, during initial (short-term) follow-up after
hospital discharge to 100 days posttransplantation,
the PBSCT group had higher costs and longer LOS
compared with the BMT group, although these
differences did not reach statistical significance. Our
results also showed a large difference in mean cost
depending on disease risk, a measure not evaluated in
the previous pediatric study [36]. Our analysis of the
ICER showed a significantly different treatment suc-
cess rate in the standard-risk and high-risk subgroups.
Although there was great variability in costs and the
group sizes were relatively small, our results appear
to be robust in sensitivity analyses of the observed
between-group differences.
We developed a cost prediction model from
detailed accounting data to estimate costs for patients
undergoing SCT between January 2001, and Septem-
ber 2003. We confirmed that there were no changes in
institutional allocation of expenses for the transplant
unit during the study period. Thus, we have no reason
to believe that any possible changes in hospital
accounting practices would bias our cost comparisons.
Based on the regression model that we developed to
impute cost data, all of the adjusted R2 values were
well above 0.90, with\10% of the variance explained
by additional variables, including possibly outcome-
relevant variables. We found that HLA-matched
related donors (donor 2) had a lower negative coeffi-
cient than HLA-mismatched sibling donors (donor
1), because the latter are perceived as being more
costly. This internal inconsistency likely results from
the small number of subjects in this study, providing
Biol Blood Marrow Transplant 16:1272-1281, 2010 1279Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Childrenan idiosyncratic outcome resulting from random
effects in a small data set.
During the first year of follow-up posttransplanta-
tion, patients mainly returned to the primary transplant
clinic for standard of care. Inclusion of outpatient costs
outside of the institution and for home care utilization
would be expected to raise the total costs of follow-up.
A previous study of patients who returned to the care
of a local physician after 100 days found that costs
incurred between 3 and 6 months posttransplantation
represented 3.8% of the total cost [29]. Although these
data were not available at our institution, we would not
expect the exclusion of those relatively minor cost
estimates to result in a significant differential increase
in costs. Because the intent of our study was to analyze
the total direct costs from the perspective of health care
providers, we did not include the costs resulting from
the time loss of patients or their families in the
transplantation program.
Although differences between institutions and in
health care structures and pricing make direct compar-
isons with our study difficult, our data can be adjusted
to factor in such differences. Precise estimates of
hospital costs are essential to an accurate evaluation,
so we used micro-costing to measure all of the direct
medical costs of allogeneic SCT for up to 1 year. These
resource-intensive transplantation services may vary at
regional and even local levels, and our results may not
be representative of other areas, even within the United
States. Nonetheless, our detailed micro-costing and
consistent cost categories allow valid comparisons of
resource requirements for the alternative therapies.
We investigated the total direct costs for up to 1
year in all patients who underwent primary transplan-
tation at our institution. Fourteen patients in our study
had multiple transplantations and were excluded from
our primary analysis, because these additional treat-
ments are one of several salvage options for primary
treatment failure and carry different, and not compara-
ble, expectations of cost and complexity, regardless of
the stem cell source. In those patients who had multi-
ple transplantations after they relapsed from their ini-
tial transplantation, we subsequently measured costs
and outcomes in separate analyses. Because this was
a retrospective observational study, accrual was subject
to selection bias; however, treatment groups were sim-
ilar in terms of age, sex, ethnicity, and insurance cover-
age. We appreciate that fewer PBSCT recipients than
BMT recipients were studied, a difference that reflects
clinical practice in pediatric SCT during the study
period. It certainly would be valuable to reanalyze
our data with a larger, more balanced cohort, which
likely would increase our confidence in our conclu-
sions. Similarly, we followed our patients for 1 year,
an intermediate health care outcome, and a longer
study would be valuable to compare the longer-term
cost-effectiveness of PBSCT and BMT.The foregoing limitations of our study notwith-
standing, cost-effectiveness analyses likely will become
increasingly important as health care policies change.
Our current ICER and analysis of uncertainty suggest
that allogeneic BMT is a more cost-effective treatment
option than PBSCT in patients with standard-risk
childhood acute leukemia. For high-risk patients, our
data are less clear, because the between-group differ-
ences were more limited and the range of costs was
much wider. Our comparative economic evaluation
provides support for BMT in standard-risk patients,
but the high degree of uncertainty in the data limits
any clear advantage for either treatment option in
patients with high-risk disease. A larger and random-
ized controlled trial, especially in high-risk patients,
is needed to definitively demonstrate the long-term
cost-effectiveness of allogeneic PBSCT and BMT in
the pediatric population.ACKNOWLEDGMENTS
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REGRESSION MODEL COST EQUATION
1. Total Costs (Initial hospitalization for SCT)5 b01
b1*Sex (male/female)1 b2*Ethnicity (Hispanic/non-
Hispanic)1 b3*Donor1 (HLA-mismatched sibling/
Other)1 b4*Donor2 (HLA-matched related/Other)
1 b5*Donor3 (HLA-matched unrelated/Other) 1
b6*CMV (D-R positive/Other) 1 b7*Disease risk
(standard/high risk)1 b8*LOS1 b9*(LOS)
21 error
2. Total Costs (After discharge to Day 1100 post
SCT: short-term follow up) 5 b0 1 b1*Sex (male/
female) 1 b2*Ethnicity (Hispanic/non-Hispanic)
1 b3*aGvHD (yes/no) 1 b4*Disease risk (stan-
dard/high risk) 1 b5*LOS 1 b6*(LOS)
2 1 error
3. Total Costs (From Day 1100 to 1 year post SCT:
long-term follow up) 5 b0 1 b1*Sex (male/female)
1 b2*Ethnicity (Hispanic/non-Hispanic) 1
b3*cGvHD (yes/no) 1 b4*Infection (yes/no)
1b5*Relapse (yes/no) 1 b6*Disease risk (standard/
high risk) 1 b7*LOS 1 b9*(LOS)
2 1 error
Table A1. Parameter coefficients and SEs of the Independent Variables Included in the Cost Regression Model
Variable Parameter Coefficient SE Adjusted R2
BMT group; BMT phase 1 (n 5 53) 0.9626
Sex (Ref* 5 Male) 3235.94 11,059
Ethnicity (Ref* 5 Hispanic) 5049.70 10,891
Disease Risk (Ref* 5 Standard Risk) 2447.55 12,343
CMV (Ref* 5 Positive) 8798.93 11,436
Donor1 (Ref* 5 HLA-mismatched sibling) 252948 30,414
Donor2 (Ref* 5 HLA-matched related) 234620 19,353
Donor3 (Ref* 5 HLA-matched unrelated) 27407.06 18,045
LOS 4828.42 1137.41
LOS2 18.50 17.11
PBSCT group; BMT phase 1 (n 5 11) 0.9705
Sex (Ref* 5 Male) 23561.99 19,307
Ethnicity (Ref* 5 Hispanic) 14,440 17,264
Disease Risk (Ref* 5 Standard Risk) 212828 18,028
CMV (Ref* 5 Positive) 0 0
Donor1 (Ref* 5 HLA-mismatched sibling) 256155 36,035
Donor2 (Ref* 5 HLA-matched related) 2136278 60,466
Donor3 (Ref* 5 HLA-matched unrelated) 215588 38,287
LOS 7209.48 1718.96
LOS2 22.18 20.24
BMT group; BMT phase 2 (n 5 53) 0.9813
Sex (Ref* 5 Male) 6606.49 5811.76
Ethnicity (Ref* 5 Hispanic) 21,592 5393.42
Disease Risk (Ref* 5 Standard Risk) 5476.39 5865.31
aGVHD (Ref* 5 Yes) 13,670 5296.64
LOS 2868.65 378.52
LOS2 75.53 6.29
PBSCT group; BMT phase 2 (n 5 11) 0.9335
Sex (Ref* 5 Male) 213,217 21,027
Ethnicity (Ref* 5 Hispanic) 38,782 17,468
Disease Risk (Ref* 5 Standard Risk) 11,976 19,088
aGVHD (Ref* 5 Yes) 25465.65 18,231
LOS 5502.20 1577.93
LOS2 5.56 25.60
BMT group; BMT phase 3 (n 5 41) 0.9118
Sex (Ref* 5 Male) 228,589 18,293
Ethnicity (Ref* 5 Hispanic) 28,434 18,366
Disease Risk (Ref* 5 Standard Risk) 30,238 20,998
cGVHD (Ref* 5 Yes) 4358.69 34,508
Relapse (Ref* 5 Yes) 23,030 38,049
Infection (Ref* 5 Yes) 528.23 21,988
LOS 6507.70 1012.9
LOS2 27.09 12.82
PBSCT group; BMT phase 3 (n 5 8) 0.9429
Sex (Ref* 5 Male) 217905 34,883
Ethnicity (Ref* 5 Hispanic) 225604 23,423
Disease Risk (Ref* 5 Standard Risk) 22,506 16,518
cGVHD (Ref* 5 Yes) 24689.58 22,303
Relapse (Ref* 5 Yes) 23,812 19,970
Infection (Ref* 5 Yes) 0 0
LOS 7761.36 2719.7
LOS2 231.27 62.19
BMT indicates bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; SCT, stem cell transplantation; aGVHD, acute graft-
versus-host disease; cGVHD, chronic graft-versus-host disease; LOS, length of stay; CMV, cytomegalovirus.
Ref*, Reference group; BMT phase 1, initial hospitalization for SCT; BMT phase 2, after discharge to day +100 post-SCT, short-term follow-up; BMT
Biol Blood Marrow Transplant 16:1272-1281, 2010 1281Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Childrenphase 3, from day +100 to 1 year post-SCT, long-term follow-up.
